Etrolizumab for Ulcerative Colitis (TNF Inhibitors Naive)
- Injection under the Skin
- Limited to 350 patients
- 1 Location
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have not tried an anti-TNF therapy (e.g. Remicade, Humira, etc.).
You may be eligible to participate if you meet the following criteria:
- Ages 18 - 80
- Male or Female
- Moderately to severely active ulcerative colitis (i.e. not in remission)
- Have not previously been treated with anti-TNF therapy
- Have not previously been treated with Entyvio (vedolizumab)
How You Can Participate
This study is currently accepting candidates. You would receive medical care from Dr. Brian Bressler at GI Research Institute. Answer a few questions to see if you can participate ›
Frequently Asked Questions
- How much does it cost?
- The treatment and doctor visits are free.
- Are traveling expenses covered?
- Travel expenses will generally be covered.
Here's a timeline of what you can expect:
Step 1: Online Pre-screener
Find out if you are a match by answering a few online questions.
Check Your Eligibility ›
Step 2: Phone Call with Care Coordinator
Speak with our Care Team specialist to confirm your candidacy.
Step 3: Screening Appointment
If you are eligible to continue, you will be given an appointment date and time to come to the clinic for a screening visit.
Other Exclusive Treatments
ABT-494 for Ulcerative Colitis
ABT-494 is an oral medication taken once daily.
Etrolizumab for Ulcerative Colitis (For patients who have previously used anti-TNFs)
This study is evaluating how safe and effective etrolizumab is compared to placebo for the treatment of moderate to severe ulcerative colitis. Participants must have failed an anti-TNF therapy (e.g. Remicade, Humira, etc.) previously.
Vedolizumab for Pouchitis
Vedolizumab is an intraveneous medication for ulcerative colitis who have had bowel surgery involving a proctocolectomy and ileal pouch anal anastomosis.